Skip to main content
Premium Trial:

Request an Annual Quote

Caris, Feist-Weiller Cancer Center Partner to Offer Tumor Profiling Services

NEW YORK (GenomeWeb) – The LSU Health Shreveport Feist-Weiller Cancer Center today announced a partnership with Caris Life Sciences to offer tumor profiling services.

As a result, patients at University Health Shreveport, a clinical partner of the LSU Health Shreveport School of Medicine, will have access to the technology, which is being provided via the Caris Molecular Intelligence service.

Caris Molecular Intelligence correlates molecular data from a tumor with biomarker and/or drug associations from clinical and scientific literature and combines traditional pathology analysis methods with DNA sequencing technologies to generate information for use in making therapeutic decisions for patients.

The partners noted that molecular profiling has become especially valuable in caring for patients with difficult-to-treat cancers, as well as for those with rare and aggressive cancers.

As part of the deal, Caris is providing clinical support, patient and physician education, and system integration. The partnership also provides a forum for joint research projects to be carried out by Caris and Feist-Weiller researchers.

"As the only institution in a 250-mile radius to offer these capabilities, our partnership with Caris is critical to providing more precise, personalized care for cancer patients treated at our center each year," said Glenn Mills, director of Feist-Weiller. "This type of technology is integral to better understanding the unique molecular characteristics of a patient's disease, which enables more targeted treatment planning."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.